Interview with the CEO of Altrixbio, Nancy Briefs

The CEO of AltrixBio, Nancy Briefs discusses their cutting-edge oral therapy platform designed to replicate the benefits of bariatric surgery without the need for invasive procedures. Their lead candidate, LuCI™ AJN 003, is a reformulation of the well-established drug sucralfate, re-engineered to create a protective mucosal barrier throughout the gastrointestinal tract. This innovation targets metabolic conditions like obesity and type 2 diabetes by promoting improved glucose regulation and weight reduction. LuCI Therapeutics aims to redefine metabolic disease treatment with a focus on safety, efficacy, and patient accessibility.

Read the Bioneex Story with AltrixBio